Reducing the immune response to immunotoxin.
Frankel
Arthur E
AE
Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. afrankel@wfubmc.edu
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000276:immunology*; D000917:Antibody Formation; D018941:Antigens, CD19 / Q000276:immunology; D018951:Antigens, CD20 / Q000276:immunology; D006801:Humans; D000922:Immunotoxins / Q000276:immunology*; D007983:Lewis Blood Group Antigens / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D018941:Antigens, CD19; D018951:Antigens, CD20; D000922:Immunotoxins; D007983:Lewis Blood Group Antigens; C094162:Lewis Y antigen; D000069283:Rituximab